{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:48:35Z","timestamp":1791809315873,"version":"4.3.4"},"reference-count":39,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Patients with immune-mediated inflammatory diseases (IMIDs) treated with disease-modifying antirheumatic drugs (DMARDs) are at increased risk of latent tuberculosis infection (LTBI) reactivation, influenced by DMARD type. This study aimed to determine LTBI prevalence using interferon-gamma release assays (IGRAs) and identify associated risk factors in IMID patients in a middle-high TB burden setting in Mexico. Methods: A cross-sectional study was conducted from July 2024 to April 2025 at an IMID clinic. Patients aged \u226518 years, either receiving DMARDs or prior to initiating treatment, were included. LTBI was diagnosed using the QuantiFERON-TB Gold Plus assay. Bivariate analysis was performed using the chi-square test, and multivariate analysis was conducted. Results: LTBI prevalence was 34.2% (95% CI 29.1\u201339.7%) according to QFT-Plus and 35.6% (95% CI 29.7\u201342.0%) according to TSTs (n = 230). Prior TB exposure was the strongest risk factor (aOR 4.20, 95% CI 1.74\u201310.12, p = 0.001), while rheumatoid arthritis was associated with a lower LTBI likelihood (aOR 0.31, 95% CI 0.16\u20130.59, p &lt; 0.001). Conclusions: A high prevalence of LTBI was observed in patients with IMIDs treated with DMARDs. Prior tuberculosis exposure was strongly associated with LTBI. These findings highlight the importance of LTBI screening in this population to prevent reactivation.<\/jats:p>","DOI":"10.3390\/jcm14144990","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:45:52Z","timestamp":1752572752000},"page":"4990","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence and Risk Factors of Latent Tuberculosis Infection Detected by IGRA in Patients with Immune-Mediated Inflammatory Diseases Before and During Biologic DMARD Therapy (TITAN Study)"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-9894","authenticated-orcid":false,"given":"Jos\u00e9 Antonio","family":"Mata-Mar\u00edn","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital de Infectolog\u00eda \u201cDr Daniel M\u00e9ndez Hern\u00e1ndez\u201d, Centro M\u00e9dico Nacional \u201cLa Raza\u201d, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Apaez-Iglesias","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital de Infectolog\u00eda \u201cDr Daniel M\u00e9ndez Hern\u00e1ndez\u201d, Centro M\u00e9dico Nacional \u201cLa Raza\u201d, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9659-746X","authenticated-orcid":false,"given":"Ana Luz","family":"Cano-D\u00edaz","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital de Infectolog\u00eda \u201cDr Daniel M\u00e9ndez Hern\u00e1ndez\u201d, Centro M\u00e9dico Nacional \u201cLa Raza\u201d, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8040-4966","authenticated-orcid":false,"given":"Juan Pablo","family":"S\u00e1nchez-Navarro","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital de Infectolog\u00eda \u201cDr Daniel M\u00e9ndez Hern\u00e1ndez\u201d, Centro M\u00e9dico Nacional \u201cLa Raza\u201d, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Edith","family":"Fern\u00e1ndez-Madinaveitia","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital General de Zona 1 A \u201cDr Rodolfo Antonio de Mucha Mac\u00edas\u201d, Instituto Mexicano del Seguro Social, Mexico City 03300, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Barriga-Angulo","sequence":"additional","affiliation":[{"name":"Laboratory Department, Hospital de Infectolog\u00eda \u201cDr Daniel M\u00e9ndez Hern\u00e1ndez\u201d, Centro M\u00e9dico Nacional \u201cLa Raza\u201d, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4175-025X","authenticated-orcid":false,"given":"Salma","family":"Triana-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital de Infectolog\u00eda \u201cDr Daniel M\u00e9ndez Hern\u00e1ndez\u201d, Centro M\u00e9dico Nacional \u201cLa Raza\u201d, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8480-0408","authenticated-orcid":false,"given":"Alberto","family":"Chaparro-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital de Infectolog\u00eda \u201cDr Daniel M\u00e9ndez Hern\u00e1ndez\u201d, Centro M\u00e9dico Nacional \u201cLa Raza\u201d, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ericka Nelly","family":"Pompa-Mera","sequence":"additional","affiliation":[{"name":"Research Unit, Hospital de Infectolog\u00eda \u201cDr Daniel M\u00e9ndez Hern\u00e1ndez\u201d, Centro M\u00e9dico Nacional \u201cLa Raza\u201d, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1600-1385","authenticated-orcid":false,"given":"Jes\u00fas Enrique","family":"Gayt\u00e1n-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital de Infectolog\u00eda \u201cDr Daniel M\u00e9ndez Hern\u00e1ndez\u201d, Centro M\u00e9dico Nacional \u201cLa Raza\u201d, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14787210.2018.1483238","article-title":"Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs","volume":"16","author":"Goletti","year":"2018","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_2","unstructured":"World Health Organization (2024). Global Tuberculosis Report 2024, World Health Organization."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMcp2108501","article-title":"Latent Tuberculosis Infection","volume":"385","author":"Shah","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jiac.2020.09.028","article-title":"Treatment of latent tuberculosis infection in patients receiving biologic agents","volume":"27","author":"Yamana","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8909834","DOI":"10.1155\/2017\/8909834","article-title":"Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics","volume":"2017","author":"Cantini","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/07853890.2014.941919","article-title":"Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: A systematic review of randomized controlled trials","volume":"46","author":"Lorenzetti","year":"2014","journal-title":"Ann. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1900655","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: A systematic review and meta-analysis","volume":"54","author":"Cohen","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1590\/S0482-50042011000100004","article-title":"Low prevalence of reactive PPD prior to infliximab use: Comparative study on a population sample of Hospital Geral de Fortaleza","volume":"51","author":"Callado","year":"2011","journal-title":"Rev. Bras. Reumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101815","DOI":"10.1016\/j.eclinm.2022.101815","article-title":"Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: An individual participant data meta-analysis","volume":"56","author":"Hamada","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sharma, S.K., Vashishtha, R., Chauhan, L.S., Sreenivas, V., Seth, D., and Hasnain, S.E. (2017). Comparison of TST and IGRA in Diagnosis of Latent Tuberculosis Infection in a High TB-Burden Setting. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169539"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s10067-017-3714-6","article-title":"Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents","volume":"36","author":"Garziera","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2004.029041","article-title":"Attenuated response to purified protein derivative in patients with rheumatoid arthritis: Study in a population with a high prevalence of tuberculosis","volume":"64","author":"Acevedo","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/apt.16952","article-title":"Review article: Latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management","volume":"56","author":"Fehily","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_14","first-page":"100600","article-title":"Tuberculosis and immigration: The challenges in the Latin American and Colombian context","volume":"27","author":"Valderrama","year":"2023","journal-title":"Lancet Reg. Health Am."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e005639","DOI":"10.1136\/bmjgh-2021-005639","article-title":"Increasing tuberculosis burden in Latin America: An alarming trend for global control efforts","volume":"6","author":"Ranzani","year":"2021","journal-title":"BMJ Glob. Health"},{"key":"ref_16","first-page":"e39743","article-title":"Prevalence of Latent Tuberculosis Infection (LTBI) in Mexican Patients with Rheumatoid Arthritis (RA)","volume":"15","author":"Zavala","year":"2023","journal-title":"Cureus"},{"key":"ref_17","unstructured":"Pan American Health Organization (2023). Tuberculosis in the Americas. Regional Report 2021, PAHO."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100194","DOI":"10.1016\/j.jctube.2020.100194","article-title":"Latent tuberculosis in migrants travelling through the northeast regions of Mexico","volume":"21","author":"Medina","year":"2020","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1086\/313864","article-title":"Mucosal bacille Calmette-Gu\u00e9rin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses","volume":"30","author":"Hoft","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/thoraxjnl-2015-207687","article-title":"The impact of BCG vaccination on tuberculin skin test responses in children is age dependent: Evidence to be considered when screening children for tuberculosis infection","volume":"71","author":"Seddon","year":"2016","journal-title":"Thorax"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s10067-016-3298-6","article-title":"Epidemiology of rheumatic diseases in indigenous populations in Latin-Americans","volume":"35","author":"Pons","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e012297","DOI":"10.1136\/bmjgh-2023-012297","article-title":"A costing framework to compare tuberculosis infection tests","volume":"8","author":"Brumwell","year":"2023","journal-title":"BMJ Glob. Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/infdis\/jiy265","article-title":"Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk and Timing of Tuberculosis Among Close Contacts of Persons with Infectious Tuberculosis","volume":"218","author":"Reichler","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Liu, Q., Yan, W., Liu, R., Bo, E., Liu, J., and Liu, M. (2022). The Association Between Diabetes Mellitus and the Risk of Latent Tuberculosis Infection: A Systematic Review and Meta-Analysis. Front. Med., 9.","DOI":"10.3389\/fmed.2022.899821"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Oren, E., Fiero, M.H., Barrett, E., Anderson, B., Nu\u00f1ez, M., and Gonzalez, S.F. (2016). Detection of latent tuberculosis infection among migrant farmworkers along the US-Mexico border. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1959-3"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/iub.2413","article-title":"Tuberculosis comorbidity with rheumatoid arthritis: Gene signatures, associated biomarkers, and screening","volume":"73","author":"Zafari","year":"2021","journal-title":"IUBMB Life"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4314\/ahs.v23i2.14","article-title":"Frequency of latent tuberculosis in patients receiving Anti-TNF-Alpha therapy","volume":"23","author":"Turan","year":"2023","journal-title":"Afr. Health Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","article-title":"Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II\/III Clinical Studies in Psoriasis and Psoriatic Arthritis","volume":"47","author":"Strober","year":"2024","journal-title":"Drug Saf."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.radcr.2022.10.032","article-title":"Active pulmonary tuberculosis in a patient with secukinumab treatment","volume":"18","author":"Ngoc","year":"2022","journal-title":"Radiol. Case Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40265-024-02131-3","article-title":"Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review","volume":"85","author":"Chihota","year":"2025","journal-title":"Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijdvl.IJDVL_791_18","article-title":"Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population","volume":"86","author":"Sarkar","year":"2020","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/ibd.21605","article-title":"Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection","volume":"17","author":"Semb","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1128\/JCM.00814-14","article-title":"Extremes of age are associated with indeterminate QuantiFERON-TB gold assay results","volume":"52","author":"Tebruegge","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e00427","DOI":"10.1128\/JCM.00427-18","article-title":"QuantiFERON-TB Gold Plus Is a More Sensitive Screening Tool than QuantiFERON-TB Gold In-Tube for Latent Tuberculosis Infection among Older Adults in Long-Term Care Facilities","volume":"56","author":"Chien","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jiac.2017.09.012","article-title":"Lymphocyte subset analysis in QuantiFERON-TB Gold Plus and T-Spot.TB for latent tuberculosis infection in rheumatoid arthritis","volume":"24","author":"Igari","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","article-title":"Safety of Biologic Therapy in Older Patients with Immune-Mediated Diseases: A Systematic Review and Meta-analysis","volume":"17","author":"Borren","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Osorio-Ch\u00e1vez, J.S., Mart\u00ednez-L\u00f3pez, D., \u00c1lvarez-Reguera, C., Portilla, V., Cifri\u00e1n, J.M., Casta\u00f1eda, S., Ferraz-Amaro, I., and Blanco, R. (2024). Epidemiology of Latent Tuberculosis in Rheumatic Immune-Mediated Inflammatory Diseases\u2014Study of 1117 Patients and Descriptive Literature Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13247546"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/14\/4990\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:09:47Z","timestamp":1760033387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/14\/4990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":39,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["jcm14144990"],"URL":"https:\/\/doi.org\/10.3390\/jcm14144990","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}